Bacterial Vaginosis: Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/028, June 2023)

Alex Farr; Sonja Swidsinski; Daniel Surbek; Brigitte Frey Tirri; Birgit Willinger; Udo Hoyme; Gisela Walter; Inge Reckel-Botzem; Werner Mendling

doi:10.1055/a-2169-8539

Geburtshilfe und Frauenheilkunde, Inhaltsverzeichnis

Geburtshilfe Frauenheilkd 2023; 83(11): 1331-1349
DOI: 10.1055/a-2169-8539

GebFra Science

Guideline/Leitlinie

Bacterial Vaginosis: Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/028, June 2023)

Artikel in mehreren Sprachen: English | deutsch

Alex Farr

¹Universitätsklinik für Frauenheilkunde, Abteilung für Geburtshilfe und feto-maternale Medizin, Medizinische Universität Wien, Wien, Austria

,

Sonja Swidsinski

²MDI Limbach Berlin GmbH, Berlin, Germany

,

Daniel Surbek

³Universitätsklinik für Frauenheilkunde, Geburtshilfe und Feto-maternale Medizin, Inselspital Bern, Universität Bern, Bern, Switzerland

,

Brigitte Frey Tirri

⁴Frauenklinik, Kantonsspital Baselland, Liestal, Switzerland

,

Birgit Willinger

⁵Abteilung für Klinische Mikrobiologie, Medizinische Universität Wien, Wien, Austria

,

Udo Hoyme

⁶Klinik für Frauenheilkunde und Geburtshilfe, Ilm-Kreis-Kliniken, Arnstadt, Germany

,

Gisela Walter

⁷Ärztliche Gesellschaft zur Gesundheitsförderung e. V. (ÄGGF), Hamburg, Germany

⁸Deutsche STI-Gesellschaft (DSTIG), Bochum, Germany

,

Inge Reckel-Botzem

⁹Berufsverband der Frauenärzte e. V. (BVF), Landesverband Hessen, Hainburg, Germany

,

Werner Mendling

¹⁰Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe, Wuppertal, Germany

› Institutsangaben

Abstract

Aim This official guideline was coordinated and published by the DGGG, OEGGG and SGGG with the involvement of additional professional societies. The aim of the guideline is to evaluate the relevant literature and use it to provide a consensus-based overview of the diagnosis and management of bacterial vaginosis.

Methods This S2k-guideline was developed by representative members from different medical professional societies on behalf of the guidelines commission of the above-listed societies using a structured consensus process.

Recommendations This guideline provides recommendations on the diagnosis, management, counselling, prophylaxis, and other aspects related to bacterial vaginosis.

Key words

bacterial vaginosis - infection - guideline

Volltext

Referenzen

Literatur
1 Peebles K, Velloza J, Balkus JE. et al. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis 2019; 46: 304-311
2 Swidsinski A, Mendling W, Loening-Baucke V. et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106: 1013-1023
3 Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169: 450-454
4 Vaneechoutte M, Guschin A, Van Simaey L. et al. Emended description of Gardnerella vaginalis and description of Gardnerella leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with delineation of 13 genomic species within the genus Gardnerella. Int J Syst Evol Microbiol 2019; 69: 679-687
5 van Esbroeck M, Vandamme P, Falsen E. et al. Polyphasic approach to the classification and identification of Gardnerella vaginalis and unidentified Gardnerella vaginalis-like coryneforms present in bacterial vaginosis. Int J Syst Bacteriol 1996; 46: 675-682
6 Sadhu K, Domingue PA, Chow AW. et al. Gardnerella vaginalis has a gram-positive cell-wall ultrastructure and lacks classical cell-wall lipopolysaccharide. J Med Microbiol 1989; 29: 229-235
7 Patterson JL, Stull-Lane A, Girerd PH. et al. Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial-vaginosis-associated anaerobes. Microbiology (Reading) 2010; 156: 392-399
8 Wertz J, Isaacs-Cosgrove N, Holzman C. et al. Temporal Shifts in Microbial Communities in Nonpregnant African-American Women with and without Bacterial Vaginosis. Interdiscip Perspect Infect Dis 2008; 2008: 181253
9 Shipitsyna E, Roos A, Datcu R. et al. Composition of the vaginal microbiota in women of reproductive age–sensitive and specific molecular diagnosis of bacterial vaginosis is possible?. PLoS One 2013; 8: e60670
10 Rosca AS, Castro J, Sousa LGV. et al. Gardnerella and vaginal health: the truth is out there. FEMS Microbiol Rev 2020; 44: 73-105
11 Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis 2016; 214 (Suppl. 01) S14-S20
12 Swidsinski A, Verstraelen H, Loening-Baucke V. et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One 2013; 8: e53997
13 Sewankambo N, Gray RH, Wawer MJ. et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350: 546-550
14 Cauci S, Monte R, Driussi S. et al. Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis. J Infect Dis 1998; 178: 1698-1706
15 Verstraelen H, Verhelst R, Nuytinck L. et al. Gene polymorphisms of Toll-like and related recognition receptors in relation to the vaginal carriage of Gardnerella vaginalis and Atopobium vaginae. J Reprod Immunol 2009; 79: 163-173
16 Ravel J, Gajer P, Abdo Z. et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4680-4687
17 Borgdorff H, van der Veer C, van Houdt R. et al. The association between ethnicity and vaginal microbiota composition in Amsterdam, the Netherlands. PLoS One 2017; 12: e0181135
18 Bautista CT, Wurapa E, Sateren WB. et al. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res 2016; 3: 4
19 Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol 2013; 209: 505-523
20 Martin DH. The microbiota of the vagina and its influence on womenʼs health and disease. Am J Med Sci 2012; 343: 2-9
21 Marrazzo JM, Fiedler TL, Srinivasan S. et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis 2012; 205: 1580-1588
22 Bradshaw CS, Walker SM, Vodstrcil LA. et al. The influence of behaviors and relationships on the vaginal microbiota of women and their female partners: the WOW Health Study. J Infect Dis 2014; 209: 1562-1572
23 Brookheart RT, Lewis WG, Peipert JF. et al. Association between obesity and bacterial vaginosis as assessed by Nugent score. Am J Obstet Gynecol 2019; 220: 476.e1-476.e11
24 Swidsinski A, Doerffel Y, Loening-Baucke V. et al. Gardnerella biofilm involves females and males and is transmitted sexually. Gynecol Obstet Invest 2010; 70: 256-263
25 Swidsinski A, Dorffel Y, Loening-Baucke V. et al. Desquamated epithelial cells covered with a polymicrobial biofilm typical for bacterial vaginosis are present in randomly selected cryopreserved donor semen. FEMS Immunol Med Microbiol 2010; 59: 399-404
26 Zozaya M, Ferris MJ, Siren JD. et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome 2016; 4: 16
27 Vodstrcil LA, Walker SM, Hocking JS. et al. Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV. Clin Infect Dis 2015; 60: 1042-1053
28 Bradshaw CS, Morton AN, Hocking J. et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193: 1478-1486
29 Francis SC, Looker C, Vandepitte J. et al. Bacterial vaginosis among women at high risk for HIV in Uganda: high rate of recurrent diagnosis despite treatment. Sex Transm Infect 2016; 92: 142-148
30 Vodstrcil LA, Hocking JS, Law M. et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One 2013; 8: e73055
31 Bradshaw CS, Sobel JD. Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis 2016; 214 (Suppl. 01) S14-S20
32 Li XD, Wang CC, Zhang XJ. et al. Risk factors for bacterial vaginosis: results from a cross-sectional study having a sample of 53,652 women. Eur J Clin Microbiol Infect Dis 2014; 33: 1525-1532
33 Klebanoff MA, Schwebke JR, Zhang J. et al. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol 2004; 104: 267-272
34 Bagnall P, Rizzolo D. Bacterial vaginosis: A practical review. JAAPA 2017; 30: 15-21
35 Onderdonk AB, Delaney ML, Fichorova RN. The Human Microbiome during Bacterial Vaginosis. Clin Microbiol Rev 2016; 29: 223-238
36 Pepin J, Deslandes S, Giroux G. et al. The complex vaginal flora of West African women with bacterial vaginosis. PLoS One 2011; 6: e25082
37 Mendling W. Vaginal Microbiota. Adv Exp Med Biol 2016; 902: 83-93
38 Hoyme UB, Eschenbach DA. [Bacterial vaginitis. Microbiology, diagnosis, therapy and complications]. Dtsch Med Wochenschr 1985; 110: 349-353
39 Lamont RF, Duncan SL, Mandal D. et al. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003; 101: 516-522
40 Joergensen JS, Kjaer Weile LK, Lamont RF. The early use of appropriate prophylactic antibiotics in susceptible women for the prevention of preterm birth of infectious etiology. Expert Opin Pharmacother 2014; 15: 2173-2191
41 Mirmonsef P, Krass L, Landay A. et al. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res 2012; 10: 202-210
42 Atashili J, Poole C, Ndumbe PM. et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (London, England) 2008; 22: 1493-1501
43 Wanga V, Mackelprang RD, Thomas KK. et al. Brief Report: Bacterial Vaginosis and Risk of HIV Infection in the Context of CD101 Gene Variation. J Acquir Immune Defic Syndr 2020; 85: 584-587
44 Mendling W. Gynäkologische Infektiologie – Diagnostik und Therapie beim Symptom Fluor. Frauenarzt 2018; 59: 65
45 Sustr V, Foessleitner P, Kiss H. et al. Vulvovaginal Candidosis: Current Concepts, Challenges and Perspectives. J Fungi (Basel) 2020; 6: 267
46 Sutton M, Sternberg M, Koumans EH. et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis 2007; 45: 1319-1326
47 Sena AC, Miller WC, Hobbs MM. et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007; 44: 13-22
48 Petrin D, Delgaty K, Bhatt R. et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998; 11: 300-317
49 Workowski KA, Bachmann LH, Chan PA. et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70: 1-187
50 Sherrard J, Wilson J, Donders G. et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS 2018; 29: 1258-1272
51 Fischer T, Mortl M, Reif P. et al. Statement by the OEGGG with Review of the Literature on the Mode of Delivery of Premature Infants at the Limit of Viability. Geburtshilfe Frauenheilkd 2018; 78: 1212-1216
52 Sobel JD, Kaur N, Woznicki NA. et al. Prognostic Indicators of Recurrence of Bacterial Vaginosis. J Clin Microbiol 2019; 57: e00227-19
53 Gardner HL, Dukes CD. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am J Obstet Gynecol 1955; 69: 962-976
54 Amsel R, Totten PA, Spiegel CA. et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74: 14-22
55 Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29: 297-301
56 Abele-Horn M, Blenk H, Clad A. Genitalinfektionen Teil I in mikrobiologisch-infektiologische Qualitätsstandards (MIQ), MIQ 10. Elsevier Verlag, Urban & Fischer; 2011
57 Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sex Transm Infect 2002; 78: 413-415
58 Swidsinski A, Loening-Baucke V, Mendling W. et al. Infection through structured polymicrobial Gardnerella biofilms (StPM-GB). Histol Histopathol 2014; 29: 567-587
59 Hong KH, Hong SK, Cho SI. et al. Analysis of the Vaginal Microbiome by Next-Generation Sequencing and Evaluation of its Performance as a Clinical Diagnostic Tool in Vaginitis. Ann Lab Med 2016; 36: 441-449
60 van den Munckhof EHA, van Sitter RL, Boers KE. et al. Comparison of Amsel criteria, Nugent score, culture and two CE-IVD marked quantitative real-time PCRs with microbiota analysis for the diagnosis of bacterial vaginosis. Eur J Clin Microbiol Infect Dis 2019; 38: 959-966
61 Eschenbach DA, Hillier S, Critchlow C. et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158: 819-828
62 Krohn MA, Hillier SL, Eschenbach DA. Comparison of methods for diagnosing bacterial vaginosis among pregnant women. J Clin Microbiol 1989; 27: 1266-1271
63 Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. J Clin Microbiol 1983; 18: 170-177
64 Coleman JS, Gaydos CA. Molecular Diagnosis of Bacterial Vaginosis: an Update. J Clin Microbiol 2018; 56: e00342-18
65 Myziuk L, Romanowski B, Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. J Clin Microbiol 2003; 41: 1925-1928
66 Bradshaw CS, Morton AN, Garland SM. et al. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J Clin Microbiol 2005; 43: 1304-1308
67 West B, Morison L, Schim van der Loeff M. et al. Evaluation of a new rapid diagnostic kit (FemExam) for bacterial vaginosis in patients with vaginal discharge syndrome in The Gambia. Sex Transm Dis 2003; 30: 483-489
68 Ravel J, Moreno I, Simon C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gynecol 2021; 224: 251-257
69 Landlinger C, Oberbauer V, Podpera Tisakova L. et al. Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance. Antimicrob Agents Chemother 2022; 66: e0231921
70 Weissenbacher ER, Donders G, Unzeitig V. et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin(R)) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest 2012; 73: 8-15
71 Mendling W, Palmeira-de-Oliveira A, Biber S. et al. An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review. Arch Gynecol Obstet 2019; 300: 1-6
72 Novakov Mikic A, Budakov D. Comparison of local metronidazole and a local antiseptic in the treatment of bacterial vaginosis. Arch Gynecol Obstet 2010; 282: 43-47
73 Briese V, Neumann G, Waldschlager J. et al. Efficacy and tolerability of a local acting antiseptic agent in the treatment of vaginal dysbiosis during pregnancy. Arch Gynecol Obstet 2011; 283: 585-590
74 Novakov Mikic A, Stojic S. Study results on the use of different therapies for the treatment of vaginitis in hospitalised pregnant women. Arch Gynecol Obstet 2015; 292: 371-376
75 Swidsinski A, Dorffel Y, Loening-Baucke V. et al. Response of Gardnerella vaginalis biofilm to 5 days of moxifloxacin treatment. FEMS Immunol Med Microbiol 2011; 61: 41-46
76 Swidsinski A, Loening-Baucke V, Swidsinski S. et al. Clue Cells and Pseudo Clue Cells in Different Morphotypes of Bacterial Vaginosis. Front Cell Infect Microbiol 2022; 12: 905739
77 McGough SF, MacFadden DR, Hattab MW. et al. Rates of increase of antibiotic resistance and ambient temperature in Europe: a cross-national analysis of 28 countries between 2000 and 2016. Euro Surveill 2020; 25: 1900414
78 Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG 2008; 115: 1369-1374
79 Coudray MS, Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol 2020; 245: 143-148
80 Gottschick C, Deng ZL, Vital M. et al. Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis. Microbiome 2017; 5: 119
81 Swidsinski A, Mendling W, Loening-Baucke V. et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008; 198: 97.e1-97.e6
82 Gaspar C, Rolo J, Cerca N. et al. Dequalinium Chloride Effectively Disrupts Bacterial Vaginosis (BV) Gardnerella spp. Biofilms. Pathogens 2021; 10: 261
83 Sobel JD, Ferris D, Schwebke J. et al. Suppressive antibacterial therapy with 0.75 % metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006; 194: 1283-1289
84 Brocklehurst PGA, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy (Review). John Wiley & Sons; 2013
85 Laxmi U, Agrawal S, Raghunandan C. et al. Association of bacterial vaginosis with adverse fetomaternal outcome in women with spontaneous preterm labor: a prospective cohort study. J Matern Fetal Neonatal Med 2012; 25: 64-67
86 Nelson DB, Hanlon A, Hassan S. et al. Preterm labor and bacterial vaginosis-associated bacteria among urban women. J Perinat Med 2009; 37: 130-134
87 Koumans EH, Kendrick JS. CDC Bacterial Vaginosis Working Group. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis 2001; 28: 292-297
88 Berger R, Abele H, Bahlmann F. et al. Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) – Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes. Geburtshilfe Frauenheilkd 2019; 79: 813-833
89 Boeke AJ, Dekker JH, van Eijk JT. et al. Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial. Genitourin Med 1993; 69: 388-392
90 Plummer EL, Bradshaw CS, Doyle M. et al. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review. PLoS One 2021; 16: e0246953
91 Wang ZB, Xin SS, Ding LN. et al. The Potential Role of Probiotics in Controlling Overweight/Obesity and Associated Metabolic Parameters in Adults: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2019; 2019: 3862971
92 Li C, Wang T, Li Y. et al. Probiotics for the treatment of women with bacterial vaginosis: A systematic review and meta-analysis of randomized clinical trials. Eur J Pharmacol 2019; 864: 172660
93 Mastromarino P, Vitali B, Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol 2013; 36: 229-238
94 Strus M, Chmielarczyk A, Kochan P. et al. Studies on the effects of probiotic Lactobacillus mixture given orally on vaginal and rectal colonization and on parameters of vaginal health in women with intermediate vaginal flora. Eur J Obstet Gynecol Reprod Biol 2012; 163: 210-215
95 De Alberti D, Russo R, Terruzzi F. et al. Lactobacilli vaginal colonisation after oral consumption of Respecta((R)) complex: a randomised controlled pilot study. Arch Gynecol Obstet 2015; 292: 861-867
96 Petersen EE, Genet M, Caserini M. et al. Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial. Arzneimittel-Forschung 2011; 61: 260-265
97 Bojovic T, Bojovic D, Boyer de la Tour FX. et al. First Line Treatment and Relief of Bacterial Vaginosis-related Vaginal Complaints with Metronidazole and Multi-Gyn(R) ActiGel. Eur Obstet Gynecol 2012; 7: 103-106
98 Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis 2015; 15: 292
99 Nansel TR, Riggs MA, Yu KF. et al. The association of psychosocial stress and bacterial vaginosis in a longitudinal cohort. Am J Obstet Gynecol 2006; 194: 381-386
100 Gaudoin M, Rekha P, Morris A. et al. Bacterial vaginosis and past chlamydial infection are strongly and independently associated with tubal infertility but do not affect in vitro fertilization success rates. Fertil Steril 1999; 72: 730-732
101 Liversedge NH, Turner A, Horner PJ. et al. The influence of bacterial vaginosis on in-vitro fertilization and embryo implantation during assisted reproduction treatment. Hum Reprod 1999; 14: 2411-2415
102 Wilson JD, Ralph SG, Rutherford AJ. Rates of bacterial vaginosis in women undergoing in vitro fertilisation for different types of infertility. BJOG 2002; 109: 714-717
103 Campisciano G, Florian F, DʼEustacchio A. et al. Subclinical alteration of the cervical-vaginal microbiome in women with idiopathic infertility. J Cell Physiol 2017; 232: 1681-1688
104 Wee BA, Thomas M, Sweeney EL. et al. A retrospective pilot study to determine whether the reproductive tract microbiota differs between women with a history of infertility and fertile women. Aust N Z J Obstet Gynaecol 2018; 58: 341-348
105 Haahr T, Humaidan P, Elbaek HO. et al. Vaginal Microbiota and In Vitro Fertilization Outcomes: Development of a Simple Diagnostic Tool to Predict Patients at Risk of a Poor Reproductive Outcome. J Infect Dis 2019; 219: 1809-1817
106 Park HJ, Kim YS, Yoon TK. et al. Chronic endometritis and infertility. Clin Exp Reprod Med 2016; 43: 185-192
107 Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44: 213-219
108 Donders GG, Zodzika J, Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother 2014; 15: 645-657
109 Cohen CR, Wierzbicki MR, French AL. et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med 2020; 382: 1906-1915
110 OʼLoughlin J, Millwood IY, McDonald HM. et al. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex Transm Dis 2010; 37: 100-104
111 McGowan I, Gomez K, Bruder K. et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS (London, England) 2011; 25: 1057-1064
112 Ardolino LI, Meloni M, Brugali G. et al. Preclinical Evaluation of Tolerability of a Selective, Bacteriostatic, Locally Active Vaginal Formulation. Curr Ther Res Clin Exp 2016; 83: 13-21
113 Murina F, Crisan C, Biris M. et al. Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: a multicenter clinical trial. Minerva Ginecol 2020; 72: 292-298
114 Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009; 36: 732-734
115 Marrazzo JM, Dombrowski JC, Wierzbicki MR. et al. Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clin Infect Dis 2019; 68: 803-809
116 Plummer EL, Vodstrcil LA, Danielewski JA. et al. Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples – A pilot study. PLoS One 2018; 13: e0190199